First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, Fabiana Letizia Cecere, Sara Pilotto, Vieri Scotti, Sabrina Rossi, Alessandro Del Conte, Emanuele Vita, Chiara Bennati, Andrea Ardizzoni, Giulio Cerea, Maria Rita Migliorino, Elisa Sala, Andrea Camerini, Alessandra Bearz, Elisa De Carlo, Francesca Zanelli, Giorgia Guaitoli, Marina Chiara Garassino, Lucia Pia Ciccone, Giulia Sartori, Luca Toschi, Filippo Gustavo Dall’Olio, Lorenza Landi, Elio Gregory Pizzutilo, Gabriele Bartoli, Cinzia Baldessari, Silvia Novello, Emilio Bria, Diego Cortinovis, Giulio Rossi, Antônio Rossi, Giuseppe Luigi Banna, Roberta Camisa, Massimo Di Maïo, Marcello Tiseo
Topics & Concepts
PembrolizumabMedicineInternal medicineLung cancerConfidence intervalAdverse effectPerformance statusProgression-free survivalRetrospective cohort studyOncologyCancerSurgeryChemotherapyImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging